Addex Therapeutics Ltd (ADXN.SW)

0,2100 +0,0050 (+2,44%) Börsenschluss: 05:31PM CET

Addex Therapeutics Ltd

Chemin des Mines, 9
Geneva 1202
Switzerland
41 22 884 1555
https://www.addextherapeutics.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 26

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Timothy Mark Dyer	Co-Founder, CEO & Director	N/A	N/A	1968
Dr. Roger G. Mills M.D.	Chief Medical Officer & Director	N/A	N/A	1957
Mr. Lénaic Teyssédou	Head of Fin.	N/A	N/A	1986
Dr. Jean-Philippe Rocher Ph.D.	Head of Discovery - Chemistry	N/A	N/A	1959
Dr. Robert Lutjens	Head of Discovery - Biology	N/A	N/A	1968
Dr. Mikhail Kalinichev Ph.D.	Head of Translational Science	N/A	N/A	1968
Dr. Werner Henrichi Ph.D.	Consultant	N/A	N/A	1943

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in CHF.

Beschreibung

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Corporate Governance

Addex Therapeutics Ltds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.